Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:05:53.233Z.
Calculation as of: 2026-10-06T15:05:53.233Z.
Quote observation: 2026-10-06T15:05:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d0d16669f7a2c0e1646e6313a61118319ccaec2b3022f40527d46d929c834448
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$243.85M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$240.60M
Price/OCF Ratio
5.79
TTM Avg
7.79
3Y Avg
7.79
5Y Avg
7.79
Market Cap
$241.69M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$243.71M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$243.82M
Price/OCF Ratio
N/A
TTM Avg
252.82
3Y Avg
252.82
5Y Avg
155.13
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioAge Labs Inc. (BIOA) | $236.82M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $237.69M | 13.29 | 11.46 | 10.55 | 21.56 |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $243.85M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $240.60M | 5.79 | 7.79 | 7.79 | 7.79 |
| MacroGenics, Inc. (MGNX)vs › | $233.59M | N/A | 62.49 | 62.49 | 62.49 |
| InflaRx N.V. (IFRX)vs › | $241.56M | N/A | N/A | N/A | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $241.69M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $243.71M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.82M | N/A | 252.82 | 252.82 | 155.13 |
| Biodesix, Inc. (BDSX)vs › | $228.42M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
